CRISPR Therapeutics 過去の業績
過去 基準チェック /06
CRISPR Therapeuticsの収益は年間平均-27%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.1% 7%割合で 減少しています。
主要情報
-27.0%
収益成長率
-25.1%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | -7.0% |
| 株主資本利益率 | -12.4% |
| ネット・マージン | -118.1% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Nov 11Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
Nov 07
Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21収支内訳
収支内訳
CRISPR Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 203 | -240 | 71 | 0 |
| 30 Jun 24 | 202 | -266 | 72 | 0 |
| 31 Mar 24 | 272 | -217 | 72 | 0 |
| 31 Dec 23 | 371 | -154 | 76 | 0 |
| 30 Sep 23 | 170 | -354 | 81 | 0 |
| 30 Jun 23 | 170 | -416 | 90 | 0 |
| 31 Mar 23 | 100 | -524 | 97 | 0 |
| 31 Dec 22 | 1 | -650 | 102 | 0 |
| 30 Sep 22 | 14 | -681 | 105 | 0 |
| 30 Jun 22 | 15 | -633 | 102 | 0 |
| 31 Mar 22 | 915 | 312 | 103 | 0 |
| 31 Dec 21 | 915 | 378 | 100 | 0 |
| 30 Sep 21 | 902 | 412 | 102 | 0 |
| 30 Jun 21 | 902 | 447 | 100 | 0 |
| 31 Mar 21 | 1 | -392 | 93 | 0 |
| 31 Dec 20 | 1 | -349 | 86 | 0 |
| 30 Sep 20 | 77 | -211 | 80 | 0 |
| 30 Jun 20 | 289 | 20 | 74 | 0 |
| 31 Mar 20 | 289 | 46 | 68 | 0 |
| 31 Dec 19 | 290 | 67 | 63 | 0 |
| 30 Sep 19 | 213 | -11 | 63 | 0 |
| 30 Jun 19 | 1 | -200 | 57 | 0 |
| 31 Mar 19 | 2 | -185 | 54 | 0 |
| 31 Dec 18 | 3 | -165 | 48 | 0 |
| 30 Sep 18 | 35 | -117 | 43 | 0 |
| 30 Jun 18 | 37 | -91 | 41 | 0 |
| 31 Mar 18 | 40 | -75 | 36 | 0 |
| 31 Dec 17 | 41 | -68 | 36 | 0 |
| 30 Sep 17 | 11 | -51 | 35 | 0 |
| 30 Jun 17 | 10 | -41 | 31 | 0 |
| 31 Mar 17 | 7 | -36 | 32 | 0 |
| 31 Dec 16 | 5 | -23 | 31 | 0 |
| 30 Sep 16 | 3 | -53 | 25 | 0 |
| 30 Jun 16 | 2 | -44 | 24 | 0 |
| 31 Mar 16 | 1 | -31 | 17 | 0 |
| 31 Dec 15 | 0 | -26 | 13 | 0 |
質の高い収益: CRSPは現在利益が出ていません。
利益率の向上: CRSPは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: CRSPは利益が出ておらず、過去 5 年間で損失は年間27%の割合で増加しています。
成長の加速: CRSPの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: CRSPは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。
株主資本利益率
高いROE: CRSPは現在利益が出ていないため、自己資本利益率 ( -12.35% ) はマイナスです。